MedTrace Logo

Predicting the Efficacy and Prognosis of Rectal Cancer Patients Based on ctDNA-MRD Technology

NCT05969938 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2023-08-01

No results posted yet for this study

Summary

The purpose of this study is to study the performance of MRD monitoring in predicting the efficacy and prognosis of neoadjuvant therapy in patients with rectal cancer, and to explore the value of MRD detection in evaluating the prognosis of patients. In this prospective study, 50 patients with stage II-III rectal cancer who are planing to receive neoadjuvant chemoradiotherapy will be enrolled. The tumor tissue will be collected by colonoscopy before treatment and blood samples will be collected before treatment and during treatment.The whole blood samples will receive MRD detection. The change rate and clearance rate of MRD during treatment will be calculated, and will be associated with imaging efficacy evaluation, pathological efficacy evaluation,and prognosis, to determine the performance of MRD in predicting and judging the efficacy of neoadjuvant chemoradiotherapy and postoperative recurrence of rectal cancer.

Conditions

  • Rectal Adenocarcinoma
  • Circulating Tumor DNA
  • Minimal Residual Disease
  • Neoadjuvant Chemoradiotherapy

Interventions

DIAGNOSTIC_TEST

MRD detection

Peripheral blood samples were collected for MRD detection before neoadjuvant chemoradiotherapy, during neoadjuvant chemoradiotherapy, and 3-4 weeks after radical surgery. For patients who achieved cCR after neoadjuvant therapy and adopted the W \& W strategy, the sampling time point was 3 months after the start of watching and waiting.

Sponsors & Collaborators

  • Haplox Biotechnology Co., Ltd.

    collaborator INDUSTRY

  • WeiWei Xiao

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-21
Primary Completion
2024-06-30
Completion
2024-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05969938 on ClinicalTrials.gov